Experimental cell therapy for advanced solid tumors with KRAS G12V mutation
Part of Cancer clinical trials.
This trial tests an experimental cell therapy that uses your own immune cells to attack cancers with a specific gene change (KRAS G12V). It may be an option if other treatments haven't worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- You must have advanced solid tumor cancer that hasn't responded to standard treatments.
- Your tumor must have a specific gene change called KRAS G12V, and you need a special immune marker called HLA-A*11:01.
- You need at least one tumor that can be measured on scans.
- You must be able to care for yourself (ECOG score 0 or 1) and be expected to live more than 6 months.
- Your heart, kidney, liver, and blood counts must be within certain limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immune cell therapy (called RE002 T cells) for people with advanced solid tumors that have a specific KRAS G12V mutation and a certain HLA type. The therapy is designed to target and attack cancer cells that carry this mutation.
This trial tests a new type of immune cell therapy (TCR-T) designed to attack cancer cells with a specific KRAS mutation. It may be an option for people with advanced solid tumors who have run out of standard treatments.
This trial tests a new treatment made from your own immune cells that are specially trained to attack cancer cells with a specific mutation called KRAS G12V. It is for people with advanced solid tumors who have run out of standard options.
This trial tests a personalized T-cell therapy designed to recognize and attack cancer cells with a specific KRAS G12V mutation. It is for people with metastatic solid tumors that have this mutation and a specific immune type (HLA-A*11:01).
This trial tests a new type of cell therapy (called TCR-T) that targets a specific genetic change (KRAS G12D) in advanced solid tumors that have stopped responding to standard treatments. It may be an option if your cancer has this mutation and you have a specific tissue type (HLA).
This trial tests a personalized T cell therapy designed to target cancer cells with specific KRAS mutations (G12V or G12D). It may be an option for people with advanced solid tumors who have exhausted standard treatments.
Hear when a new KRAS G12V trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.